Effects of Ginkgo biloba extract (EGb 761) on cognitive control functions, mental activity of the prefrontal cortex and stress reactivity in adult healthy volunteers.

Trial Profile

Effects of Ginkgo biloba extract (EGb 761) on cognitive control functions, mental activity of the prefrontal cortex and stress reactivity in adult healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Sep 2016

At a glance

  • Drugs EGb 761 (Primary)
  • Indications Alzheimer's disease; Cognition disorders
  • Focus Pharmacodynamics
  • Sponsors Dr. Willmar Schwabe Pharmaceuticals
  • Most Recent Events

    • 06 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by German Clinical Trials Register record.
    • 06 Jul 2012 Planned end date (23 Apr 2012) added as reported by German Clinical Trials Register record.
    • 23 Apr 2012 Status changed from active, no longer recruiting to completed as reported by German Clinical Trials Register record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top